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Summary
 
The islet-infiltrating and disease-causing leukocytes that are a hallmark of insulin-dependent di-
abetes mellitus produce and respond to a set of cytokine molecules. Of these, interleukin 1
 
b
 
,
tumor necrosis factor (TNF)-
 
a
 
, and interferon (IFN)-
 
g
 
 are perhaps the most important. How-
ever, as pleiotropic molecules, they can impact the path leading to 
 
b 
 
cell apoptosis and diabetes
at multiple points. To understand how these cytokines influence both the formative and effec-
tor phases of insulitis, it is critical to determine their effects on the assorted cell types compris-
ing the lesion: the effector T cells, antigen-presenting cells, vascular endothelium, and target
islet tissue. Here, we report using nonobese diabetic chimeric mice harboring islets deficient in
specific cytokine receptors or cytokine-induced effector molecules to assess how these com-
partmentalized loss-of-function mutations alter the events leading to diabetes. We found that
islets deficient in Fas, IFN-
 
g
 
 receptor, or inducible nitric oxide synthase had normal diabetes
development; however, the specific lack of TNF-
 
 a
 
 receptor 1 (p55) afforded islets a profound
protection from disease by altering the ability of islet-reactive, CD4
 
1
 
 T cells to establish insuli-
 
tis and subsequently destroy islet 
 
b 
 
cells. These results argue that islet cells play a TNF-
 
a
 
–depen-
dent role in their own demise.
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I
 
nsulin-dependent diabetes mellitus (IDDM)
 
1
 
 is an auto-
immune disease caused by the T cell-mediated destruc-
tion of the insulin-producing 
 
b
 
 cells of the pancreatic islets
of Langerhans (1, 2). The nonobese diabetic (NOD) mouse
spontaneously develops IDDM remarkably similar to that
seen in humans (2, 3). The disease process is characterized
by an initial, silent and nondestructive accumulation of a het-
erogeneous mixture of CD4
 
1
 
 and CD8
 
1
 
 T lymphocytes, B
lymphocytes, macrophages, and dendritic cells (4, 5) circum-
scribing the islet mass, termed peri-insulitis. An invasive
and malignant phase follows, termed insulitis, during which
the immune infiltrate invades the islet and induces the speci-
fic apoptotic destruction of 
 
b 
 
cells (6–8). The events lead-
ing to insulitis induction, its perpetuation, and the subse-
quent destruction of 
 
b 
 
cells are poorly understood.
Cytokines produced by the immune infiltrate itself are
clearly involved in the propagation of insulitis, but their
pluripotentiality has made it difficult to pinpoint their spe-
cific roles in diabetes. Nevertheless, TNF-
 
a
 
, IFN-
 
g
 
, and
IL-1
 
b
 
 have all been implicated as critical players in the dis-
ease process. As these are all potent proinflammatory mole-
cules with the capability of affecting events critical to insu-
litis such as the expression of adhesion molecules (9), the
upregulation of MHC molecules (10), and the localized
production of chemoattractants (11), it is not surprising to
see a varied, and often conflicting, set of effects ascribed to
them during the course of IDDM development.
TNF-
 
a
 
, which is secreted principally by activated mac-
rophages and CD4
 
1
 
 Th1 cells (for review see references
12, 13), can, for example, either retard or exacerbate the
development of IDDM in NOD mice depending on when
and where it acts (14–20). Thus, although these experi-
ments reveal the potent ability of TNF-
 
a
 
 to alter the devel-
opment of autoimmune diabetes, the specific role TNF-
 
a
 
normally plays in diabetes development has not yet been
fully elucidated.
The effect of IFN-
 
g
 
 on IDDM is less clear. On the one
hand, a number of studies have revealed a critical role for
IFN-
 
g
 
 in the induction of insulitis and subsequent devel-
opment of diabetes (21, 22). On the other hand, an abso-
 
1
 
Abbreviations used in this paper:
 
 CFSE, 5,6-carboxy-succinimidyl-fluores-
cein-ester; IDDM, insulin-dependent diabetes mellitus; iNOS, inducible
NO synthase; NO, nitric oxide; NOD, nonobese diabetic. 
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lute deficiency of the IFN-
 
g
 
 gene in NOD mice had little
effect on the overall development of diabetes (23).
To further complicate matters, many proinflammatory cy-
tokines not only promote inflammation but may also facili-
tate the localized destruction of target tissue. For example,
IFN-
 
g
 
, TNF-
 
a
 
, and IL-1
 
b
 
 have all been implicated in
the cytolysis of a number of cell types, including pancreatic
 
b
 
 cells (24, 25). TNF-
 
a
 
 and IFN-
 
g
 
 have been shown to
directly induce apoptosis (24–26), whereas IL-1
 
b
 
 may act
indirectly through the induction of reactive nitric oxide
(NO) intermediates to islet cell destruction (27–29). Here
again, the pluripotent nature of cytokines has made it diffi-
cult to dissect and ascribe precisely what role they play in
the actual destruction of 
 
b 
 
cells in vivo.
Similarly, understanding 
 
b 
 
cell death has been hampered
by the inability to study individual apoptotic pathways in
isolation. This is perhaps best exemplified by recent studies
on Fas (CD95) as a potential inducer of 
 
b 
 
cell apoptosis
(30, 31). Although Fas-deficient NOD mice (NOD
 
lpr/lpr
 
)
do not develop diabetes, the global loss of Fas expression in
these mice affects not only the pancreatic 
 
b 
 
cell but the
critical T and B lymphocyte populations as well. Therefore,
it is difficult to assign the protection from diabetes seen in
these mice to the inability to kill Fas-deficient 
 
b 
 
cells or to
the gross abnormalities found in adaptive immunity.
How then does one root out the multiple effects cy-
tokines have on a complex autoimmune disease such as
IDDM? Here, we report the use of chimeric NOD mice
carrying islets deficient in one of several defined cytokine
receptors or cytokine-induced effector molecules as a means
of specifically and physiologically isolating the target islet
tissue from the effects of locally produced cytokines. In this
way, we can examine the effect islet-specific deficiencies in
Fas, IFN-
 
g
 
R, inducible NO synthase (iNOS), and TNFR
have on the development of IDDM in NOD mice when
confronted by a population of diabetogenic CD4
 
1
 
 T cells.
Contrary to previous reports, we found that Fas, IFN-
 
g
 
R,
and iNOS deficiencies did not alter the development of
diabetes. However, the specific deficiency of the TNF-
 
a
 
receptor 1 (p55) rendered these islets profoundly imper-
meable to islet-reactive T cells. In fact, in the absence of
an islet response to locally produced TNF-
 
a
 
, infiltrating
T cells failed to proliferate, establish insulitis, and subse-
quently destroy islet 
 
b 
 
cells. Not only do these results argue
that TNF-
 
a
 
 is a key player in the development of diabetes,
they argue that this molecule must act in part upon the tar-
get tissue. Therefore, the islet must play an active, and
TNF-
 
a
 
–dependent, role in its own demise.
 
Materials and Methods
 
Mice.
 
BDC2.5 TCR transgenic mice have been described
previously (32). B6.
 
lpr
 
 mice were obtained from Dr. John Rus-
sell (Washington University, St. Louis, MO), who originally ob-
tained congenic breeding pairs from The Jackson Laboratory.
These mice were backcrossed 
 
.
 
12 generations to C57Bl/6 (B6)
and were maintained by brother/sister mating. IFN-
 
g
 
R–deficient
mice (33) were obtained on a 129 background from Dr. M.
 
Aguet (Institut de Recherche sur le Cancer, Epalinges, Switzer-
land). TNFR p55-deficient (34) and p75-deficient (35) mice
were obtained as doubly deficient mice on a mixed 129 
 
3 
 
B6
background from Dr. R.D. Schreiber (Washington University;
with permission from Drs. W. Lesslauer, Roche, Basel, Switzer-
land, and M. Moore, Genentech, South San Francisco, CA). A
control TNF-
 
a
 
 wild-type line was derived from negative litter-
mates and used as controls in all TNF-
 
a
 
 receptor experiments.
Mice deficient in iNOS (36) were obtained from Taconic Farms
on a pure 129/SvEv background by permission of Dr. J. Mudgett
(Merck Research, Rahway, NJ). All mice were bred and housed
under specific pathogen free conditions. All donor islets were de-
rived from the original knockout or mutant lines as indicated
above, unless specifically noted in the text. Mice deficient in the
p55 receptor were backcrossed onto NOD.
 
scid
 
 for seven genera-
tions and intercrossed to generate p55-deficient NOD.
 
scid
 
 mice.
 
Flow Cytometry.
 
Flow cytometry was performed on a Becton
Dickinson FACScan
 
®
 
. We purchased PE-conjugated anti-CD4
(Caltag Labs.), anti-B220 (PharMingen) and goat anti–mouse
IgM (Jackson ImmunoResearch Labs.). The mAb to the 
 
b 
 
chain
of the transgenic TCR, anti-V
 
b
 
4 (37), was conjugated with
FITC. List mode data was collected on 10
 
5
 
 cells and reanalyzed on
a PC using WinMDI (version 2.7) software written by J. Trotter
(http://facs.scripps.edu).
 
Diabetes.
 
Diabetes was assessed by measurement of venous
blood using a Bayer Glucometer Elite one-step blood glucose
meter. Animals were considered diabetic after two consecutive
measurements 
 
$
 
250 mg/dl (13.75 mM). Onset of diabetes was
dated from the first consecutive reading.
 
Streptozotocin Treatment.
 
Streptozotocin was prepared fresh for
each set of injections in sodium citrate–buffered saline. NOD.
 
scid
 
mice were weighed and streptozotocin was injected intravenously
at a dose of 180 mg/kg, after which most mice became diabetic
(
 
.
 
400 mg/dl) within 48–72 h. Diabetic mice were transplanted
with islets within 48–72 h of the onset of diabetes.
 
Islet Isolation and Culture.
 
Mouse islets were isolated by colla-
genase technique (38) and purified on Ficoll gradient. Individual
clean islets were selected and cultured overnight at 24
 
8
 
C in 5%
CO
 
2
 
 in DMEM supplemented with 5% FCS (Hyclone), 10 mM
Hepes, 5 
 
3
 
 10
 
2
 
5
 
 M 2-ME, penicillin (100 U/ml), streptomycin
sulfate (100 
 
m
 
g/ml), and glutamine (2 mM).
 
Islet Transplantation.
 
250 islets from mutant or control mice
(all H-2
 
b
 
 on either a 129 or B6 background) were transplanted un-
der the renal capsule of streptozotocin-induced diabetic NOD.
 
scid
 
mice as previously described (39). In brief, under anesthesia (87
mg/kg of sodium pentobarbital), islets were transplanted under
the renal capsule by exposing the left kidney through a flank inci-
sion, pushing the kidney through the incision, and holding it in
place with small clamp attached to fatty tissue; with the aid of a
dissecting microscope the capsule was cut with a needle and islets
were then delivered through the incision by a Hamilton syringe
fitted with a polyethylene catheter. After the catheter was with-
drawn and the capsule was sealed by a small, pen-size eyecautery,
the kidney was returned to the abdomen and the incision was
closed. Normoglycemia was reestablished within 24 h of success-
ful transplantation. Mice were then rested for 10–14 d to allow
for vascularization of the graft by host vascular endothelium be-
fore the introduction of diabetic T cells. In the mixed islet grafts,
the number of islets was 300 (200 p55
 
2/2
 
 and 100 wild-type).
Transplants were performed in a similar manner on bilateral kid-
neys with a total of 300 islets being transplanted per mouse. In all
experiments, mice not receiving diabetogenic T cells remained
normoglycemic (80–110 mg/dl) for 
 
.
 
180 d. Confirmation of the 
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graft’s support of normoglycemia was verified by nephrectomy of
engrafted kidney. All transplants and manipulation of the mice
were performed following written protocols that had the prior
approval of the Washington University School of Medicine Ani-
mal Studies Committee. All necessary steps were taken to mini-
mize the discomfort of the transplanted animals.
 
Nephrectomy.
 
Mice were anesthetized with 87 mg/kg of so-
dium pentobarbital and the engrafted kidney was exposed by a
flank incision as above. The engrafted kidney was raised and freed
from fatty tissue as before. The renal artery and vein along with
the ureter were clamped off with a mosquito hemostat and were
sutured distal to the kidney with 4-0 silk. The kidney was cut
free with a scalpel. The clamp was released slowly and the suture
was inspected for leaks and the incision closed.
 
Immunohistochemistry.
 
Kidney graft sections were stained
with antibodies against V
 
b
 
4 (KT4), macrophages (ERMP-23;
reference 40), dendritic cells (NLDC-145; Harlan sera labs), mad-
CAM (MECA-367; reference 41), and peripheral node addressin
(MECA-79; reference 41) as previously described (42).
 
T Cell Proliferation.
 
In vitro
 
 
 
T cell proliferation to islet cell
antigen was performed as previously described (32). In vivo
 
 
 
T cell
proliferation was performed using the cell surface dye, 5,6-carboxy-
succinimidyl-fluorescein-ester (CSFE). Preparation and labeling
of T cells with CSFE was performed as described in reference 43.
CSFE-labeled BDC2.5 T cells (10
 
7
 
 cells) were transferred intra-
venously in to NOD.
 
scid
 
 mice carrying kidney grafts of either
250 p55-deficient or 250 p55-sufficient islets. T cells from the
draining lymph nodes (peri-renal) were collected on the indi-
cated day after transfer and analyzed by flow cytometer for evi-
dence of cell division.
 
Results and Discussion
 
The ability to target loss-of-function mutations to spe-
cific organ systems remains a major challenge. With the ex-
ception of certain mutations targeted to the immune sys-
tem using the Rag-mutant complementation system (44) or
the inducible knockouts (45), it has been difficult to study the
effects of broadly expressed or broadly acting mutations on
specific organ systems or disease models. This is particularly
true of the ubiquitously expressed cytokine receptors and
their pluripotent ligands, the cytokine molecules themselves.
Several experimental models have long suggested that
cytokines influence the development of autoimmune dia-
betes (for review see reference 46). Although these models
have been informative, it has remained difficult to attribute
particular stage dependency to any given cytokine, especially
under physiological conditions. Moreover, it has been diffi-
cult to determine what cellular conduit channels the action
of each cytokine; is it through the effector lymphocyte, the
APC, the vascular epithelium, or the islet tissue itself? There-
fore, we undertook to develop a novel approach that com-
partmentalizes the action of cytokines and their receptors to
specific cellular targets in an effort to establish the depen-
dency of particular phases of diabetes development to the
local effect of these mediators.
We did this by creating chimeric NOD mice. Unlike
prior models, these mice harbored wild-type NOD APCs
that express the disease-associated MHC class II, I-A
 
g7
 
, and
wild-type NOD vascular endothelium. Moreover, they
carried a defined population of diabetogenic CD4
 
1
 
 T cells
(BDC2.5 TCR transgenic T cells) that respond to pancre-
atic 
 
b
 
 cell antigen, presented uniquely by NOD APCs, and
are capable of mediating the autoimmune destruction of
pancreatic 
 
b
 
 cells (32, 47–49). What distinguishes our cur-
rent approach was the prior replacement of the endogenous
 
b
 
 cells with those derived from one of several mouse strains
deficient in key cytokine receptor or proapoptotic effector
molecules. In so doing, we created chimeric NOD mice
containing altered 
 
b
 
 cell target tissue. This allowed us to as-
sess the potential impact of each genetic alteration on the
islet cell’s ability to serve as a target for autoimmune-medi-
ated destruction by altering the host effector lymphocyte,
APC, or vascular endothelium.
As shown schematically in Fig. 1, NOD.
 
scid
 
 mice were
treated with streptozotocin, a 
 
b
 
 cell toxin, to destroy en-
dogenous 
 
b
 
 cells, producing a chemically-induced diabetes
(
 
$
 
400 mg/dl). Normoglycemia (
 
,
 
100 mg/dl) was rapidly
returned with the transplantation of 
 
z
 
250 islets under the
left kidney capsule. (It should be noted that the donor islets
can be from any strain of mouse as NOD.
 
scid
 
 do not reject
allogeneic tissue. We routinely used islets of H-2
 
b
 
 donors.)
The rescued mice were then rested for 7–10 d, allowing for
host-derived vascularization of the graft. At this point,
splenic T cells from diabetic BDC2.5/NOD.
 
scid
 
 mice were
transferred into these chimeric NOD.
 
scid
 
 mice, and the
mice were followed for onset of diabetes.
These experiments are predicated on the following ob-
servations. First, as mentioned above, the recipient mice
are 
 
scid
 
, hence they do not reject allogeneic islet grafts, as
confirmed by control experiments where each series of do-
nor islets are engrafted under the kidney capsule and the
mice are left unmanipulated for 
 
.
 
180 d. None of these mice
develop diabetes during this period. Moreover, the trans-
planted islets are functional, and are responsible for the
maintenance of normoglycemia, as removal of the en-
grafted kidney results in hyperglycemia (data not shown).
Second, the BDC2.5 T cells do not recognize the 
 
b
 
 cells
directly but rather require the transfer of islet antigen to
NOD (H-2
 
g7
 
) APCs, which are supplied by the NOD.
 
scid
recipient mice. Third, although the recognition of antigen
Figure 1. Schematic representation of transplantation protocol. 6–8-wk-
old healthy NOD.scid mice were injected with Streptozotocin to render
them chemically diabetic (.400 mg/dl). Within 48–72 h of the onset of
diabetes, the mice were engrafted with 250–300 islets under the left kid-
ney capsule. Normoglycemia returned within 24 h of islet transplantation.
The mice were then rested 7–10 d, during which time host-derived vas-
cular support for the grafts developed. Splenic T cells from overtly dia-
betic BDC2.5/NOD.scid mice were transferred into the engrafted-
NOD.scid mice (day 0). Mice were followed thereafter for the onset of
diabetes. At day 28, normoglycemic mice were nephrectomized.1056 p55-mediated Islet Response Is Needed for Progression to Diabetes
is MHC restricted, all strains of mice express the relevant
antigen in their pancreatic b cells (48). And finally, once
activated by antigen, BDC2.5/NOD.scid T cells can medi-
ate the destruction of islet b cells in NOD.scid mice (6).
Destruction of Pancreatic b Cells in the Absence of Fas. Pan-
creatic b cell death during the course of T cell–mediated
diabetes is by apoptosis (6–8). One potential mediator of b
cell apoptosis is Fas (CD95). The engagement of Fas, a pro-
apoptotic member of the TNFR family, on the surface of
target cells by Fas ligand–expressing T lymphocytes leads to
the apoptotic destruction of the Fas-expressing target cell
(for review see reference 50). Treatment with IFN-g in-
duces the expression of Fas on the surface of a variety of
cell types including b cells (24). Moreover, islet-infiltrating
T cells can induce Fas expression on b cells through local-
ized production of IFN-g (31). Additionally, Fas-deficient,
NODlpr/lpr mice do not develop diabetes (30, 31); however,
these mice had substantially altered T and B cell immunity
(30). These results notwithstanding, it has not been formally
demonstrated that Fas expression on b cells is required for
their autoimmune-mediated destruction.
To test whether Fas expression on b cells is obligatory,
we used our chimeric NOD mice model to create mice
specifically lacking Fas expression on their islet cells. This
was done by either eliminating the islet’s ability to respond
to IFN-g by replacing the existing islet mass with islets
lacking the IFN-gR or by using islets from B6.lpr/lpr mice
that lack functional Fas expression as islet donors. After
transplant, T cells from diabetic BDC2.5/NOD.scid mice
were transferred into these mice and diabetes onset was fol-
lowed. We found that BDC2.5 T cells destroyed B6.lpr/lpr
islets as efficiently as control B6 islets, as shown in Fig. 2 a,
indicating that Fas does not play an obligatory role as the
critical inducer of b cell destruction, at least with respect to
disease transferred by diabetogenic CD41 T cells. Similarly,
when NOD.scid mice were transplanted with islets defi-
cient in IFN-gR, the chimeric mice developed diabetes
at the same rate as control islet grafts (129/SvJ; Fig. 2 b).
These results clearly demonstrate that islet cell Fas expres-
sion, either induced or constitutive, is not required for islet
destruction by diabetogenic CD41 T cells. Moreover, this
would suggest that much of the protection seen in Fas-defi-
cient NOD mice results from altered lymphoid develop-
ment in the absence of Fas expression on T and B lympho-
cytes. Parenthetically, these results help to clarify the role
IFN-g may play in diabetes development. Wang et al., in
describing the introduction of systemic IFN-g receptor
deficiency onto the NOD background, found that both
NOD and BDC2.5/NOD mice lacking IFN-gR had se-
verely retarded insulitis development (21). Our results
would suggest that this is probably due to an effect IFN-g
has on the T cells, APCs, or host endothelium but not on
the islet mass itself.
Islet Cell Production of Reactive Nitric Oxide Intermediates Is
Not Required for b Cell Destruction. Previous studies have
indicated that IL-1 stimulates the production of nitric oxide
(NO) either by priming for Fas-mediated apoptosis or by
inducing the inducible form of the NO synthase gene
(iNOS or NOS2; references 51, 52). iNOS-mediated NO
production can lead to b cell death in vitro (27–29). NO
can be produced by the islets themselves or by the infiltrat-
ing macrophage/dendritic population. We found that the
in vivo neutralization of IL-1b with a cocktail of antibodies
and soluble receptor did not prevent NOD mice from be-
coming diabetic (data not shown), leading us to question its
role in b cell death. However, to examine the effect that
the targeted iNOS deficiency in islets had on b cell destruc-
tion, we tested the ability of iNOS-deficient islets to resist T
cell–mediated destruction. As shown in Fig. 2 b, iNOS-defi-
cient islets were destroyed with similar kinetics and magni-
tude as wild-type islets, indicating that iNOS gene expres-
sion is not critical for islet cell apoptosis. Although this result
does not rule out a role for NO production by infiltrating
macrophage/dendritic cells, it clearly demonstrates that is-
lets themselves do not need to produce intracellular NO to
undergo T cell–mediated elimination.
TNF-aR Deficiency Affords Islets Protection from Diabeto-
genic CD41 T Cell–mediated Destruction. TNF-a, which is
secreted principally by activated macrophages and CD41
Th1 cells (12, 13), can both retard and exacerbate the de-
Figure 2. TNF-aRI (p55)–defi-
cient islets are protected from destruc-
tion by diabetogenic CD41 T cells,
whereas Fas-deficient, IFN-gR–defi-
cient, iNOS-deficient, and TNF-aR
p75 islets are destroyed. (a) 250
B6.lpr/lpr (d, n 5 12) or control B6
islets (s, n 5 10) transplanted under
the kidney capsule are destroyed. h,
diabetes in control NOD.scid mice
transferred with the same population
of T cells (n 5 9). (b) 250 IFN-gR–
deficient (r,  n  5 7), iNOS-defi-
cient (j, n 5 6) or control 129 islets
(n, n 5 8) transplanted under the
kidney capsule are destroyed. (c)
Transplanted p552/2 islets (., n 5 9) and p552/2p752/2 doubly deficient islets (m, n 5 10) are protected from destruction by transferred T cells from di-
abetic BDC2.5/NOD.scid mice, whereas p752/2 islets (,, n 5 11) are destroyed. Diabetes is measured by sampling venous blood using a standard one-
step glucometer. Mice are considered diabetic after two successive readings $250 mg/dl. In all cases, engrafted mice that did not receive diabetogenic T
cells remained normoglycemic throughout the experimental period (.180 d); moreover, the engrafted islets were responsible for normoglycemia, as the
hemi-nephrectomy of engrafted kidneys returned mice to hyperglycemia.1057 Pakala et al.
velopment of IDDM in NOD mice largely dependent on
the time of its administration (14–16). Thus, when TNF-a
is given to NOD mice from birth to 3 wk of age, diabetes
is accelerated, and conversely the administration of neutral-
izing antibody to TNF-a during this period markedly re-
duces both insulitis and diabetes (16). Yet when adminis-
tered to adult NOD mice with established insulitis, TNF-a
attenuates the disease process, and its antibody neutraliza-
tion exacerbates diabetes (16, 53). Moreover, the transgenic
expression of TNF-a in the islets of adult NOD mice leads
to insulitis without disease (17–19) and produces a state of
T cell tolerance to islet cell antigens (19, 20). Thus, although
these experiments reveal the potent ability of TNF-a to al-
ter the development of autoimmune diabetes, the physio-
logical role played by TNF-a has yet to be fully elucidated.
To investigate the role that localized production of TNF-a
can have on the development of diabetes, we transplanted
streptozotocin-treated NOD.scid mice with islets rendered
doubly deficient for both TNF-aRs (TNF-aR1, p55;
TNF-aR2, p75). As before, the transfer of diabetogenic T
cells led to the rapid destruction of wild-type islet grafts (7 out
of 8); however, doubly deficient islets (p552/2p752/2) re-
mained functional (Fig. 2 c). Mice engrafted with p552/2
p752/2 islets remained normoglycemic for up to 52 d after
the transfer of T cells. To confirm that the introduced is-
lets were responsible for the maintenance of blood glucose,
normoglycemic p552/2p752/2 islet recipients were hemi-
nephrectomized at day 28 to remove the engrafted kidney.
As shown in Fig. 2 c, these mice became hyperglycemic
within 24 h of nephrectomy, proving that the transplanted
p552/2p752/2 islets were indeed responsible for the main-
tenance normoglycemia. Interestingly, the mice carrying
p552/2p752/2 islets contained BDC2.5 T cells as measured
by flow cytometric analysis of spleen and lymph node. In
addition, these T cells were phenotypically normal in that
they could still transfer disease to unmanipulated NOD.scid
mice (data not shown).
To assess which receptor conferred the protection, we
produced chimeric mice carrying islets defective in either
the p55 receptor or the p75 receptor. Fig. 2 c shows that
p552/2 islets were protected from T cell–mediated destruc-
tion, whereas the p752/2 islets were efficiently destroyed.
All the p752/2 transplanted mice (11 out of 11) became
diabetic by day 12, whereas the p552/2 transplanted mice
(9 out of 9) remained normoglycemic until end of the assay
($28 d). We therefore concluded that the engagement of
the p55 receptor by locally produced TNF-a was critical in
the subsequent destruction of b cells.
p552/2 Islets and p752/2 Islets Are Equally Antigenic to
BDC2.5 T Cells. One explanation for the lack of islet
destruction of the p552/2 grafts is that the p552/2 islets are
non- or poorly antigenic. To test this, BDC2.5 T cells were
cocultured with NOD APCs in the presence of dispersed
p552/2 and p752/2 islet cells for 72 h under standard condi-
tions, and T cell proliferation was measured. As shown in
Fig. 3, BDC2.5 T cells proliferated equally well to both
receptor-deficient islet cells, indicating that islet cell anti-
genicity does not depend on TNF-aR expression. We per-
formed a similar assay with intact islets in vitro in the pres-
ence and absence of exogenous recombinant TNF-a and
were unable to detect a difference in the induced prolifera-
tion of BDC2.5 T cells (data not shown). We therefore
concluded that at least in vitro, there is no difference in the
antigenicity of p552/2 and p752/2 islet cells. This is some-
what discordant with recent results by Green et al., who
reported that the localized production of TNF-a in b cells
of transgenic NOD mice enhanced autoantigen presenta-
tion to BDC2.5 T cells in vitro (54).
The CD41 T Cell Infiltration of p552/2 Islet Grafts Does
Not Progress into Destructive Insulitis. An alternative explana-
tion for the p55-deficient islets’ resistance to T cell–medi-
ated destruction resides with a fundamental modification in
the cellular constituency of the infiltrate. To evaluate this
possibility, we performed an immunohistochemical analysis
of both p552/2 and wild-type (or p752/2) islet grafts after T
cell transfer. Engrafted kidneys were sampled at day 5, 7,
and 9 after T cell transfer as well as at the time of diabetes
or in the case of normoglycemic mice at day 28. As seen in
Fig. 4, there was no infiltration in either p55-deficient or
wild-type islet grafts at day 5. At day 7, however, the wild-
type graft showed distinct signs of peri-islet accumulation
of leukocytes, with some grafts showing evidence of intra-
islet infiltration and destruction. The same was not true for
the p55-deficient islet grafts, which showed only modest
peri-islet infiltration and no intra-islet infiltration. As seen
in Fig. 4, the most dramatic difference was revealed at day
9 when the wild-type islet grafts were completely infil-
trated. These islets showed discrete foci of apoptotic b cells
as revealed by TUNEL analysis (data not shown). In con-
trast, the p55-deficient islet grafts were only mildly infil-
trated at day 9 (Fig. 4) and showed no signs of apoptosis
(data not shown). Moreover, by day 13, the wild-type islet
grafts were destroyed and the mice were overtly diabetic.
Surprisingly, the mild infiltration of the p552/2 grafts failed
to progress, and in fact resolved, so that by day 28 they
were nearly indistinguishable from those seen on or before
day 5. We therefore concluded that the p552/2 islet grafts
could not sustain the infiltrating CD41 T cells and that
the propagation of destructive insulitis requires a TNF-a–
dependent response on part of the islets.
We then asked if the composition of the infiltrate was
modified between the p552/2 and wild-type lesions. We
compared the cellular components of the transient infiltra-
tion of p55-deficient islet grafts at day 9 with those of the
Figure 3. TNFR-deficient islet
cells are antigenic to BDC2.5 T
cells. 2 3 104 BDC2.5 T cells
were cocultured with 2.5 3 105
irradiated NOD splenic APCs
and varying numbers of either
dispersed islet cells from control
129 (n), p55-deficient (.) or
p75-deficient (,) donors. After
72 h, the assay was pulsed with
[3H]TdR for 6 h to measure T
cell proliferation to antigen. Data
are depicted as mean 6 SD.1058 p55-mediated Islet Response Is Needed for Progression to Diabetes
wild-type grafts. In general, the composition of the infil-
trate was similar to that seen in the pancreata of NOD.scid
recipients of T cells from diabetic BDC2.5 mice (42). More-
over, we saw no difference between the p552/2 and the
wild-type grafts in the activation state of the high endo-
thelial venule (HEV) as revealed by staining for madCAM
(MECA 367) and peripheral node addressin (MECA 79,
data not shown). We were also able to identify the pres-
ence of roughly equal numbers of BDC2.5 T cells in both
infiltrates as revealed by Vb4 (KT4) and anti-CD4 staining.
Both lesions contained similar subsets of macrophage (F4/80,
MOMA 1, MOMA 2) and dendritic cells (NLDC-145) as
well. Despite these similarities, there was one striking dif-
ference between the p552/2 and wild-type grafts: the com-
plete absence of b cell apoptosis in the p55-deficient grafts
(data not shown). We therefore concluded that apart from
the lack of continued progression of the lesions and the
lack of b cell apoptosis, there was little difference in the na-
ture of the infiltrates and the vascular endothelium between
wild-type and p55-deficient islet grafts.
NOD.scid Mice Lacking the p55 Receptor, but Carrying Wild-
type Islets, Develop Diabetes upon BDC2.5 T Cell Transfer.
To verify that the resistance to diabetes resided with the
p55-deficient islets rather than with the host endothelium
or APC populations, reciprocal transplants were performed
in which wild-type islets (from 129 mice) were transplanted
under the kidney capsule of streptozotocin-treated p55-defi-
cient NOD.scid mice (N7 generation). Under these condi-
tions, both the host vasculature and APC population lacked
p55 receptor expression, whereas the engrafted islet mass
retained full p55 functionality. When purified diabetogenic
CD41 T cells were transferred into these mice, diabetes de-
veloped with similar kinetics in both these mice and con-
trol recipients (Fig. 5 a). This indicated that functional ex-
pression of the p55 receptor on the islet mass alone was
sufficient to drive b cell destruction regardless of the p55
receptor expression status of the host APCs and the vascular
endothelium.
An Islet Graft Containing both p55-deficient and p55-suffi-
cient Islet Mass Is Destroyed upon Diabetogenic BDC2.5 T Cell
Transfer. Although the p55-deficient islets were no less
antigenic than the p55-sufficient islets and were equally ca-
pable of attracting similar subsets of infiltrating leukocytes,
they were clearly incapable of providing a microenviron-
ment that supported the maturation of the immune response
to a point were b cell death could occur. This could be for
one of two reasons. First, the propagation of insulitis may
require TNF-a–mediated b cell death. In this case, the
TNF-a produced locally by the infiltrating T cells and
macrophages would fail to kill the p55-deficient b cells and
insulitis would subside due to a lack of b cell damage. This
would be consistent with our failure to observe b cell apop-
tosis in p55-deficient islets during the early phase of infil-
tration, yet it also seemed unlikely as ectopic expression of
super-physiologic levels of TNF-a by the islets of trans-
genic mice did not lead to b cell death or diabetes (17–19,
55). Alternatively, the evolution of insulitis from a benign
accumulation of leukocytes to a destructive infiltrate may
require a TNF-a–dependent change in the islet mass—either
Figure 4. TNFR (p55) expression on the islet mass is necessary for sus-
tained infiltration of islets. Histological analysis of the progression of insu-
litis in p55-deficient islet grafts and control islet grafts (p75-deficient or
129-negative littermates) at the indicated time after transfer of T cells
from diabetic BDC2.5/NOD.scid mice. Engrafted kidneys were fixed in
buffered 10% formalin, embedded, and sectioned (4 mm). Sections were
stained with hematoxylin and eosin to show infiltration and islet architec-
ture. A representative image from one of three mice at each time point is
shown. Original magnification: 3400.
Figure 5. Reciprocal islet transplants and mixed transplants of p55-
deficient and p55-sufficient islets are destroyed upon BDC2.5 T cell infiltra-
tion. (a) Reciprocal transplants of p55-sufficient islets transplanted under
the kidney capsule of p552/2 NOD.scid mice (d, n 5 9) are destroyed as
efficiently as p551/1 islets transplanted under the kidney capsule of p551/2
NOD.scid mice (s, n 5 4). (b) Both control islet grafts (s; 300 islets; n 5
4) and mixed islet grafts (d; 200 p55-deficient islets and 100 control islets;
n 5 8) are destroyed with similar kinetics upon transfer of T cells from
diabetic BDC2.5/NOD.scid mice. Diabetes is measured by sampling
venous blood using a standard one-step glucometer. Mice are considered
diabetic after two successive readings $250 mg/dl.1059 Pakala et al.
the release of an islet cell–produced chemoattractant or acti-
vation factor or an alteration in the secretion or production
of antigen (something we are unable to mimic in vitro, but
which has been observed by others, see reference 54). Ei-
ther way, the net result would be the full activation of the
infiltrating BDC2.5 T cell population such that it can now
act to target b cells for destruction in a TNF-a–indepen-
dent fashion.
To distinguish between these two possibilities, we de-
signed and produced chimeric NOD.scid mice that carried
mixed grafts containing both varying amounts of p55-defi-
cient and p55-sufficient islets. If TNF-a acted strictly as
a cytolytic agent, only the p55-sufficient islets would be
destroyed upon transfer of diabetogenic T cells, while the
p55-deficient islets would be spared and normoglycemia
would be maintained, provided that adequate amounts of
p55-deficient islets were included in the mixed graft. On
the other hand, if TNF-a acted to alter the local environ-
ment in favor of T cell activation, the presence of even a
modicum of TNF-a–responsive islets would result in T cell
activation and the destruction of both the p55-deficient
and -sufficient islets and diabetes.
We first ascertained the minimum number of islets re-
quired in our grafts to maintain a persistent state of nor-
moglycemia in our Streptozotocin-treated NOD.scid mice.
We found that as few as 100 islets could maintain blood
glucose levels at #100 mg/dl (data not shown). Therefore,
for our initial experiments we chose to mix $200 p55-defi-
cient islets with z100 wild-type islets per graft. In this way,
the “protected” p55-deficient islets were in sufficient ex-
cess to assure normoglycemia if all of the wild-type islets
were destroyed. As before, mixed islet recipients received
diabetogenic T cells 7–10 d after islet transplantation. As
depicted in Fig. 5 b, both the mixed islet recipients and the
control mice engrafted with 300 wild-type islets developed
diabetes with comparable kinetics (between days 16 and 18
after transfer). In subsequent experiments, the numbers of
wild-type islets were reduced until as few as 10 wild-type
islets were mixed with z300 p55-deficient islets, yet the
results (islet graft destruction and diabetes) were the same
(data not shown). Therefore, we concluded from these ex-
periments that the stimulation of islet cells through their
p55 receptor altered the local environmental conditions fa-
voring the development of a productive BDC2.5 T cell in-
filtrate.
The Physical Separation of p55-deficient and p55-sufficient Is-
let Grafts on Opposing Kidneys Still Allows for the In Vivo Acti-
vation of Diabetogenic CD41 T Cells, the Destruction of b Cells
and the Development of Diabetes. Having determined that a
small number of islet cells can, in response to locally pro-
duced TNF-a, support the transition from benign to de-
structive insulitis, it was now critical to determine if this
was a purely localized effect. To address this, we performed
kidney grafts on streptozotocin-treated NOD.scid mice in
which wild-type islets (100 islets) were engrafted under the
right kidney capsule and p55-deficient islets (250 islets)
were engrafted under the left kidney capsule of the same
animal. By physically separating the grafts we sought to
minimize the effects between the wild-type and p55-defi-
cient graft. If, upon transfer of diabetogenic T cells, the
p55-deficient graft survived in these mice, despite the de-
struction of the wild-type islet grafts, then the original de-
struction of the p55-deficient islets in the mixed islet grafts
described above (Fig. 5 b) resulted merely by virtue of their
intimate proximity to the wild-type islets. On the other hand,
if the distant p55-deficient grafts were likewise destroyed, it is
more likely that the transferred T cells were altered by an
encounter with wild-type islet cells.
We found that the twin-kidney engrafted NOD.scid
recipient mice did, in fact, become diabetic 12–16 d after
receiving BDC2.5 T cells, at a rate coincidental with the
development of diabetes in mice harboring dual wild-type
grafts (Fig. 6 a). As before, those mice engrafted with only
p55-deficient islets did not develop disease. Additionally,
histological analysis of the p55-deficient bilateral graft
showed signs of b cell apoptosis within 1 d of the onset of
destructive infiltration of the p55-sufficient graft (zday 5–7
after transfer, Fig. 6 b). The ability of wild-type grafts to in-
fluence the outcome of the contralateral p55-deficient
grafts indicated that TNF-a responsiveness on the part of
the wild-type islets led to the activation of the transferred
BDC2.5 T cells such that they were now capable of hom-
ing to and destroying the p55-deficient graft on the oppo-
site kidney.
These results led us to assess the in vivo proliferative sta-
tus of BDC2.5 T cells after transfer. We reasoned that the
lack of progression in the p55-deficient islet engrafted mice
may be due to the inability of the p552/2 islets to fully ac-
tivate the transferred BDC2.5 T cells. In the mixed and
twin-kidney graft experiments, the wild-type islets would
Figure 6. Spatial separation of the p55-deficient and p55-sufficient islet
grafts on opposing kidneys does not protect the p55-deficient grafts from
destruction. (a) In dual-kidney grafts, control NOD.scid mice were en-
grafted with p55-sufficient islet grafts under both kidneys (s; 200 islets
on left kidney and 100 islets on the right) and experimental mice were
engrafted with 200 p55-deficient islets on the left kidney and 100 p55-
sufficient islets on the right kidney (d). Both sets of mice received T cells
from BDC2.5/NOD.scid mice. In both cases the engrafted islets were de-
stroyed with similar kinetics. Mice engrafted with p55-deficient islets only
(m) did not develop diabetes. Diabetes is measured by sampling venous
blood using a standard one-step glucometer. Mice are considered diabetic
after two successive readings $250 mg/dl. (b) Photomicrographs of the
contralateral kidney grafts 14 d after transfer of T cells. Engrafted kidneys
were fixed in buffered 10% formalin, embedded, and sectioned (4 mm).
Sections were stained with hematoxylin and eosin to show infiltration and
islet architecture. Note that the grafts are destroyed and only show residual
scar tissue remains of both the p55-deficient graft, left, and the p55-suffi-
cient graft, right. Representative images are from one of four mice analyzed
at this time point. Original magnification: 3400.1060 p55-mediated Islet Response Is Needed for Progression to Diabetes
provide an environment capable of furnishing this activa-
tion and therefore of leading to the subsequent destruction
of the p552/2 islets in a TNF-a–independent fashion. If this
were true, T cell proliferation in vivo might differ between
mice harboring only p552/2 islets and those carrying only
wild-type islets. This was tested by monitoring the degree
of in vivo proliferation of the BDC2.5 T cells in the effer-
ent lymph of mice harboring one or the other islet grafts
under the left kidney using the decay of the integral mem-
brane dye, CSFE, as an indicator of cell division (43, 56,
57). As depicted in Fig. 7, draining lymph nodes from mice
engrafted with p552/2 islets were devoid of reactivated
BDC2.5 T cells, whereas the renal lymph nodes from mice
engrafted with wild-type islets contained T cells that clearly
had undergone several rounds of replication. Therefore, we
concluded that the most likely explanation for the infiltra-
tion and subsequent destruction of p552/2 islets in both the
mixed and twin-kidney grafts was due in part to the activa-
tion of the BDC2.5 T cells in response to wild-type islets
either proximal or distal to the p552/2 islets. This process
required a TNF-a response on the part of the target islet
cells but the subsequent destruction of the islet tissue was
TNF-a–independent. The nature of the TNF-a response
on the part of islets remains unknown, but could be an in-
crease in antigen delivery either in direct response to TNF-a
or as a result of islet cell death. In either case, this leads to
the subsequent activation of our infiltrating islet-reactive
BDC2.5 T cells, which then act to mediate the destruction
of islet b cells in a process that does not require TNF-a.
Using the same BDC2.5 TCR transgenic model, André
et al. have proposed two checkpoints in the progression of
diabetes, the first the formation of a benign infiltrate and
the second the transition to destructive insulitis (58). We
would propose that the transition through checkpoint two
is dependent on the active response of islets to TNF-a.
Moreover, our results are consistent with the hypothesis
that early and local production of TNF-a in the islet acts to
enhance the islet’s antigenicity and the subsequent activa-
tion of disease-causing lymphocytes (16, 17, 53).
In conclusion, these data, taken together, demonstrate
that Fas, IFN-g, and iNOS do not play an obligatory role
in the apoptotic destruction of pancreatic b cells induced
by a diabetogenic CD41 T cell population, but that TNF-a
plays a critical role in the transformation of islet-reactive
CD41 T cells from a benign state of b cell indifference to
an activated state of b cell reactivity. Moreover, these re-
sults suggest, for the first time, that the islet cells themselves
play an active and TNF-dependent role in facilitating their
own death by providing an environment capable of perpet-
uating T cell–mediated insulitis.
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